Organon & Co.

OGN • Drug Manufacturers - General

$13.78

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$3.73B

Growth

-6.6%

Cash Flow

5/5

Trend

Stable

Evidence

Stable or improving margins · 3.0%Positive free cash flow · 2.07Consistent free cash flow · 5/5Reasonable earnings multiple · 9.95Healthy liquidity · 1.82

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$13.78

Change0.00%

Shares Out270.45M

Market Cap$3.73B

Enterprise Value$11.15B

52W Range5.69 - 13.60

Beta1.54

P/E17.83

P/S0.61

P/B3.70

P/FCF10.26

EV/Sales1.82

Price$13.78

Change0.00%

Shares Out270.45M

Market Cap$3.73B

Enterprise Value$11.15B

52W Range5.69 - 13.60

Beta1.54

P/E17.83

P/S0.61

P/B3.70

P/FCF10.26

EV/Sales1.82

EV/EBITDA8.94

EV/FCF30.70

Earnings Yield5.61%

FCF Yield9.74%

Dividend Yield0.50%

Gross Margin54.09%

Oper. Margin20.67%

Profit Margin3.01%

Debt/Eq11.70

Current Ratio1.82

Quick Ratio1.82

Revenue 5Y-6.63%

FCF 5Y-20.63%

Target$13.00

Target Upside-5.66%

Target Median$13.00

Target Range12.00 - 14.00

Volume1.19M

Avg Volume6.44M

EPS Surprise-0.12

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

48/100

Financial Strength

Debt, cash, stability

58/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

90/100

Why this score▼

Stable or improving margins · 3.0%Positive free cash flow · 2.07Consistent free cash flow · 5/5Reasonable earnings multiple · 9.95Healthy liquidity · 1.82High debt level · 11.7

Analyst view

Analyst sentiment and price target

OGN

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

44/100

Bearish

Bullish

Hold

Bearish

Price Target

2026-08-06

Low

$8.00

Mean

$11.33

Median

$12.00

High

$14.00

Company Overview

IPO: 5/14/2021

Industry: Drug Manufacturers - General

P/B i: 3.70

Debt / Equity i: 11.70

Operating Margin: 20.67%

Net Margin: 3.01%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 11.70

Current Ratio: 1.82

Quick Ratio: 1.82

Status: Good

Warnings

High debt level

Insider Transactions

Recent executive and insider activity

Drinane Juliana Papa

Transaction: 08/05/2026

SELL

Change

-14,761

Price

$13.57

Filing

08/05/2026

Type

SELL

ESSNER ROBERT

Transaction: 06/12/2026

BUY

Change

—

Price

Not reported

Filing

06/15/2026

Type

BUY

Ezekowitz Alan

Transaction: 06/12/2026

BUY

Change

—

Price

Not reported

Filing

06/15/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Drinane Juliana Papa	SELL	-14,761	$13.57	08/05/2026	08/05/2026
ESSNER ROBERT	BUY	—	Not reported	06/12/2026	06/15/2026
Ezekowitz Alan	BUY	—	Not reported	06/12/2026	06/15/2026
Gayle Helene D	BUY	—	Not reported	06/12/2026	06/15/2026
LAZARUS ROCHELLE B	BUY	—	Not reported	06/12/2026	06/15/2026
Leone Deborah R	BUY	—	Not reported	06/12/2026	06/15/2026
Ozuah Philip	BUY	—	Not reported	06/12/2026	06/15/2026
Patton Cynthia M	BUY	—	Not reported	06/12/2026	06/15/2026
Sequeira Ramona	BUY	—	Not reported	06/12/2026	06/15/2026
Sharp Shalini	BUY	—	Not reported	06/12/2026	06/15/2026
Holzbaur Lynette	BUY	—	$13.35	05/06/2026	05/07/2026
Morrissey Joseph T. Jr.	SELL	-2,221	$5.70	03/31/2026	04/02/2026
Morrissey Joseph T. Jr.	SELL	-7,795	Not reported	03/31/2026	04/02/2026
Holzbaur Lynette	SELL	-1,212	$5.70	03/31/2026	04/02/2026
Holzbaur Lynette	SELL	-6,715	Not reported	03/31/2026	04/02/2026
Nisita Vittorio	SELL	-1,578	$5.70	03/31/2026	04/02/2026
Nisita Vittorio	SELL	-4,606	Not reported	03/31/2026	04/02/2026
Weaver Kirke	SELL	-1,767	$5.70	03/31/2026	04/02/2026
Weaver Kirke	SELL	-6,201	Not reported	03/31/2026	04/02/2026
Falcione Aaron	SELL	-2,306	$5.70	03/31/2026	04/02/2026

About the Company

Organon & Co.

Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.

Source - link

Peers

ALVO AUPH AVDL GRDN HRMY MD NUVB PAHC SEM TLRY

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA. Project Highlights Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal system, geologically similar to AngloGold Ashanti's Arthur Project El Gigante contains two separate quartz veins up to and exceeding three metres wide and over 350 metres long with strong similarities to the surface expression of First Majestic's Ermitaño vein.

Accesswire

Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

Bank of America Corp DE reduced its position in shares of Organon and Co. (NYSE: OGN) by 58.5% in the quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 738,502 shares of the company's stock after selling 1,041,346 shares during the period. Bank of America

Defense World

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.

GlobeNewsWire

Organon & Co. (NYSE:OGN) Sets New 52-Week High – Still a Buy?

Organon and Co. (NYSE: OGN - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock had previously closed at $13.75. Analyst Ratings Changes Several research firms have recently weighed in

Defense World

Orogen Royalties Acquires a Royalty on the Haldane Silver Project

VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it has acquired a 2% Net Smelter Return ("NSR") royalty (the "Royalty") on the Haldane silver project in Yukon Territory, Canada. Haldane Royalty Highlights 1,2,3,4 Haldane is a high-grade silver project owned by Silver North Resources Ltd.

Accesswire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-04-30	0.83	0.71	-0.12
2026-02-12	0.73	0.63	-0.1
2025-11-10	0.93	1.01	0.08
2025-08-05	0.94	1	0.06
2025-05-01	0.89	1.02	0.13
2025-02-13	0.92	0.9	-0.02
2024-10-31	0.9	0.87	-0.03
2024-08-06	1.06	1.12	0.06
2024-05-02	0.97	1.22	0.25
2024-02-15	0.8	0.88	0.08
2023-11-02	1.04	0.87	-0.17
2023-08-08	0.97	1.31	0.34